Cargando…
Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients
The US Food and Drug Administration has registered 13 multiple sclerosis (MS) disease-modifying therapies (DMTs). The medications are not interchangeable as they vary in route of administration, efficacy, and safety profile. Selecting the appropriate MS DMT for individual patients requires shared de...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828681/ https://www.ncbi.nlm.nih.gov/pubmed/27104069 http://dx.doi.org/10.1212/CPJ.0000000000000208 |
_version_ | 1782426631635206144 |
---|---|
author | Bourdette, Dennis N. Hartung, Daniel M. Whitham, Ruth H. |
author_facet | Bourdette, Dennis N. Hartung, Daniel M. Whitham, Ruth H. |
author_sort | Bourdette, Dennis N. |
collection | PubMed |
description | The US Food and Drug Administration has registered 13 multiple sclerosis (MS) disease-modifying therapies (DMTs). The medications are not interchangeable as they vary in route of administration, efficacy, and safety profile. Selecting the appropriate MS DMT for individual patients requires shared decision-making between patients and neurologists. To reduce costs, insurance companies acting through pharmacy benefit companies restrict access to MS DMTs through tiered coverage and other regulations. We discuss how policies established by insurance companies that limit access to MS DMTs interfere with the process of shared decision-making and harm patients. We present potential actions that neurologists can take to change how insurance companies manage MS DMTs. |
format | Online Article Text |
id | pubmed-4828681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-48286812016-04-21 Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients Bourdette, Dennis N. Hartung, Daniel M. Whitham, Ruth H. Neurol Clin Pract Commentary The US Food and Drug Administration has registered 13 multiple sclerosis (MS) disease-modifying therapies (DMTs). The medications are not interchangeable as they vary in route of administration, efficacy, and safety profile. Selecting the appropriate MS DMT for individual patients requires shared decision-making between patients and neurologists. To reduce costs, insurance companies acting through pharmacy benefit companies restrict access to MS DMTs through tiered coverage and other regulations. We discuss how policies established by insurance companies that limit access to MS DMTs interfere with the process of shared decision-making and harm patients. We present potential actions that neurologists can take to change how insurance companies manage MS DMTs. Lippincott Williams & Wilkins 2016-04 /pmc/articles/PMC4828681/ /pubmed/27104069 http://dx.doi.org/10.1212/CPJ.0000000000000208 Text en © 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Commentary Bourdette, Dennis N. Hartung, Daniel M. Whitham, Ruth H. Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients |
title | Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients |
title_full | Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients |
title_fullStr | Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients |
title_full_unstemmed | Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients |
title_short | Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients |
title_sort | practices of us health insurance companies concerning ms therapies interfere with shared decision-making and harm patients |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828681/ https://www.ncbi.nlm.nih.gov/pubmed/27104069 http://dx.doi.org/10.1212/CPJ.0000000000000208 |
work_keys_str_mv | AT bourdettedennisn practicesofushealthinsurancecompaniesconcerningmstherapiesinterferewithshareddecisionmakingandharmpatients AT hartungdanielm practicesofushealthinsurancecompaniesconcerningmstherapiesinterferewithshareddecisionmakingandharmpatients AT whithamruthh practicesofushealthinsurancecompaniesconcerningmstherapiesinterferewithshareddecisionmakingandharmpatients |